Precision Biosciences (DTIL) Stock Forecast & Price Target

Precision BioSciences is supported by a differentiated ARCUS platform that is now generating first clinical evidence of direct cccDNA elimination in HBV, with 38 doses across 16 patients and biopsy, pgRNA, and HBsAg data that triangulate on source-level antiviral activity. Its two wholly owned lead programs in HBV and DMD create a compelling risk/reward setup: PBGENE-DMD has FDA-cleared IND status, live sites, and the prospect of near full-length dystrophin in up to ~60% of DMD patients, while PBGENE-HBV could shift chronic hepatitis B toward a finite, biomarker-guided viral cure. Despite high-risk/high-reward development stages, the company’s clinical momentum and differentiated mechanism strengthen the long-term fundamental thesis.

Precision BioSciences is viewed negatively because its valuation depends on highly uncertain assumptions, including only a 20% probability of success for PBGENE-DMD and 40% for the partnered allogeneic CD19 CAR-T program, despite both carrying substantial clinical and commercialization risk. The outlook is further pressured by the need to fund development with approximately $100M in gross equity raises in 2027E, which could dilute existing shareholders and adds meaningful capital markets risk. Although the model implies about $1.5 billion in total firm value using a 12% discount rate, a 6.0x terminal EBITDA multiple, and ARCUS-related revenues starting in 2030, reimbursement and pricing risks remain significant.